CYP1A2 Genetic Polymorphisms are Associated with Treatment Response to the Antidepressant Paroxetine
- 1 November 2010
- journal article
- research article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 11 (11) , 1535-1543
Abstract
Paroxetine is a drug of choice in the treatment of major depressive disorder (MDD). Its metabolism has recently been reported to be mediated through the CYP enzymes 1A2 and 2D6. In our current study, we tested whether genetic polymorphisms in CYP1A2 are associated with the treatment efficacy and side effects of paroxetine. A total of 241 MDD patients who had taken paroxetine continually for 8 weeks were recruited, and their steady state paroxetine concentrations were measured at weeks 2, 4 and 8. The genotypes of these patients were then assessed for the presence of nine SNPs, which were selected from either the HapMap Chinese ethnic group, the literature report or through their functional role in the CYP1A2 gene. The allele types for SNPs rs4646425 (permutation p = 0.03), rs2472304 (permutation p = 0.01) and rs2470890 (permutation p = 0.004) demonstrated significant associations with paroxetine treatment remission at week 8. Response rates in the Hamilton Rating Scale for Depression (HAM-D) and for The Hamilton Rating Scale for Anxiety (HAM-A) were significantly associated with the SNPs rs4646425 (p = 0.0126 and 0.0088 for HAM-D and HAM-A, respectively) and rs4646427 (p = 0.0067 and 0.0196 for HAM-D and HAM-A, respectively). The inducible SNP rs762551 had a significant association with paroxetine dose at week 4 (permutation p = 0.012). We did not find an association between these SNPs and the side effects or serum concentrations of paroxetine. Genetic variants in the CYP1A2 region may be indicators of treatment response in MDD patients to paroxetine.Keywords
Funding Information
- National Science Council, Taiwan (NSC 96-2314-B-400-001, NSC 97-2314-B-400-001-MY3)
- National Health Research Institutes, Taiwan (MD-095-PP-01, MD-095-PP-02, MD-097-PP-14, PH-98, 99-PP-46)
- National Research Program for Genomic Medicine (NSC 98-3112-B-400-011)
- GlaxoSmithKline
- Lilly and Janssen
- Wyeth
- Eli Lilly
This publication has 39 references indexed in Scilit:
- Response and remission criteria in major depression – A validation of current practiceJournal of Psychiatric Research, 2010
- Identification of Cytochrome P450 Isoforms Involved in the Metabolism of Paroxetine and Estimation of Their Importance for Human Paroxetine Metabolism Using a Population-Based SimulatorDrug Metabolism and Disposition, 2010
- Patients with depressive disorder, their co-morbidity, visiting rate and disability in relation to self-evaluation of physical and mental health: a cross-sectional study in family practiceBMC Family Practice, 2009
- Pharmacogenetics of anxiolytic drugsJournal of Neural Transmission, 2009
- FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritizationNucleic Acids Research, 2006
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolitesActa Psychiatrica Scandinavica, 1989
- Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit.Psychological Bulletin, 1968
- A Coefficient of Agreement for Nominal ScalesEducational and Psychological Measurement, 1960
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960